166 related articles for article (PubMed ID: 1624967)
1. A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group.
J Clin Epidemiol; 1992 Aug; 45(8):849-60. PubMed ID: 1624967
[TBL] [Abstract][Full Text] [Related]
2. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.
Shepherd J
Am J Cardiol; 1995 Sep; 76(9):113C-117C. PubMed ID: 7572679
[TBL] [Abstract][Full Text] [Related]
3. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
Shepherd J; Cobbe SM; Ford I; Isles CG; Lorimer AR; MacFarlane PW; McKillop JH; Packard CJ
N Engl J Med; 1995 Nov; 333(20):1301-7. PubMed ID: 7566020
[TBL] [Abstract][Full Text] [Related]
4. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study.
Am J Cardiol; 1995 Sep; 76(7):485-91. PubMed ID: 7653449
[TBL] [Abstract][Full Text] [Related]
5. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
6. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group.
Am J Cardiol; 1997 Mar; 79(6):756-62. PubMed ID: 9070554
[TBL] [Abstract][Full Text] [Related]
7. A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group.
J Atheroscler Thromb; 1996; 3(2):95-104. PubMed ID: 9226461
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of the West of Scotland Coronary Prevention Study.
Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
[TBL] [Abstract][Full Text] [Related]
9. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study.
Shepherd J; Gaw A;
Med Princ Pract; 2002; 11 Suppl 2():17-30. PubMed ID: 12444307
[TBL] [Abstract][Full Text] [Related]
10. [WOSCOPS [West of Scotland Coronary Prevention Study]].
Furutani N; Tada N
Nihon Rinsho; 2001 Mar; 59 Suppl 3():387-92. PubMed ID: 11347100
[No Abstract] [Full Text] [Related]
11. The cardiovascular event reduction tool (CERT)--a simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS).
L'Italien G; Ford I; Norrie J; LaPuerta P; Ehreth J; Jackson J; Shepherd J
Am J Cardiol; 2000 Mar; 85(6):720-4. PubMed ID: 12000046
[TBL] [Abstract][Full Text] [Related]
12. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
Lim PO; Yee KM
Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
[No Abstract] [Full Text] [Related]
13. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group.
J Clin Epidemiol; 1995 Dec; 48(12):1441-52. PubMed ID: 8543958
[TBL] [Abstract][Full Text] [Related]
14. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.
Lancet; 1996 Nov; 348(9038):1339-42. PubMed ID: 8918276
[TBL] [Abstract][Full Text] [Related]
15. Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
Shepherd J
Am J Cardiol; 1998 Nov; 82(10B):57T-59T. PubMed ID: 9860377
[TBL] [Abstract][Full Text] [Related]
16. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
[TBL] [Abstract][Full Text] [Related]
17. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
[TBL] [Abstract][Full Text] [Related]
18. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
19. Lipid-lowering for prevention of coronary heart disease: what policy now?
Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
[TBL] [Abstract][Full Text] [Related]
20. The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study.
J Am Coll Cardiol; 1999 Mar; 33(4):909-15. PubMed ID: 10091815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
